NCT03723928招募中不适用
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 739
- 试验地点
- 1,440
- 主要终点
- Assessment of whether patients monitored with STMDDM have non-inferior overall survival compared with patients monitored with usual care
研究概览
简要总结
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
详细描述
PRIMARY OBJECTIVES:
I. To assess whether patients with HER-2 negative, hormone receptor positive, metastatic breast cancer who are monitored with serum tumor marker directed disease monitoring (STMDDM) have non-inferior overall survival compared to patients monitored with usual care.
SECONDARY OBJECTIVES:
I. To compare cumulative direct healthcare costs through 48 weeks among patients monitored with STMDDM versus those monitored with usual care in this patient population.
II. To assess whether the patient-reported outcomes (PROs) of anxiety and quality of life (QOL) are different among patients who are monitored with STMDDM compared with patients who are monitored with usual care in this patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •STEP 1 REGISTRATION
- •Patients must have a diagnosis of hormone receptor positive (estrogen receptor positive [ER+] and/or progesterone receptor positive [PR+]), HER-2 negative, metastatic (M1) breast cancer and must be receiving or plan to receive first-line systemic treatment for metastatic disease. (Systemic treatment is any treatment meant to treat the whole body such as endocrine therapy +/- targeted therapy +/- chemotherapy).
- •NOTE: Participants are eligible if they have either de-novo metastatic breast cancer and/or recurrent breast cancer from an earlier stage that is now metastatic
- •Patients must be registered to step 1 between 14 days prior to and 60 days after start of first-line systemic treatment for metastatic disease
- •Patients must have been tested for the following breast cancer specific STMs after diagnosis of metastatic disease and within +/-14 days of initiation of first-line systemic treatment for metastatic disease:
- •CEA (must be tested)
- •CA 15-3 or CA 27.29 (at least one of these must be tested)
- •At least one of the tested STMs must have been >= 1.5 x the institutional upper limit of normal at this time.
- •Testing all three STMs is encouraged but only two are required. Patients must plan to have the same two STMs tested for the duration that the patient is on protocol-specified disease monitoring.
- •Patients must have systemic radiographic imaging prior to initiation of systemic therapy or within 30 days of initiation of treatment for metastatic breast cancer and prior to step 1 registration. Modality of imaging is at the discretion of the treating physician.
- •Note: the treating physician can order additional imaging tests at any point prior to randomization at their discretion
- •Patients must be willing to obtain disease monitoring (imaging and/or serum tumor markers) from a consistent facility in which the registering site has access to the results for the duration of the study intervention (312 weeks after step 2 randomization). Imaging and STMs do not need to be completed at the same facility.
- •Patients with known cirrhosis, untreated B12 deficiency, thalassemia, or sickle cell anemia are not eligible as these could cause falsely elevated STM levels
- •Patients with known brain leptomeningeal metastases are not eligible as they may require regular radiographic monitoring to assess treatment response
- •Patients must not be currently enrolled or plan to participate in a first-line treatment trial for metastatic breast cancer with a defined monitoring schedule
- •Patients who are able to complete questionnaires in English or Spanish must participate in patient-reported outcome (PRO) assessments
- •Patients must not be pregnant due to the potential harm to the fetus from radiation exposure from radiographic imaging
- •Except for breast cancer (and previous history of breast cancer), no other prior malignancy is allowed with the following exceptions:
- •Adequately treated basal (or squamous cell) skin cancer
- •Any cancer from which the patient has been disease free for five years
- •Prior Stage 0 or pre-cancerous lesions that have been removed with clear margins
- •Patients must not have received prior systemic therapy for metastatic breast cancer, except for their current line of therapy.
- •Patients must have decision making capacity and be able to provide informed consent
- •Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines; use of legally-authorized representative is not permissible for this study. Remote consent is allowed with adequate documentation.
- •As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
- •STEP 2 RANDOMIZATION
- •Patients must be tested for the breast cancer specific STMs that were tested prior to STEP 1 Registration between 56 and 140 days after initiation of first-line systemic therapy for metastatic disease:
- •CEA (must be tested)
- •CA 15-3 or CA 27.29 (whichever was tested prior to Step 1)
- •Testing all three STMs is encouraged but only two are required. Patients must plan to have the same two STMs tested for the duration that the patient is on protocol-specified disease monitoring.
- •At least one of the STMs that was previously elevated must have decreased from the assessment at step 1 by >= 10% at this time.
- •Patients must not have known progression since registration to step 1
- •Patients must be registered to step 2 randomization between 56 days and 140 days after the initiation of first-line systemic therapy for metastatic disease; This window is inclusive; patients may be registered to Step 2 on day 56 or Day
- •Patients must have been eligible for Step 1 in order to be eligible for Step 2 Randomization
- •Baseline questionnaires must be completed within 28 days prior to step 2 randomization; (Note: Those patients who cannot complete the PRO questionnaires in English or Spanish can be registered to step 2 without contributing to PRO research)
排除标准
- 未提供
结局指标
主要结局
Assessment of whether patients monitored with STMDDM have non-inferior overall survival compared with patients monitored with usual care
时间窗: Up to 312 weeks after randomization
The assessment of whether patients monitored with STMDDM have non-inferior overall survival compared with patients monitored with usual care will be based on multivariable Cox regression, adjusting for intervention assignment (intention-to-treat) and the stratification factor (bone only versus visceral disease). If at the time of final analysis the study shows notably fewer events than anticipated, extended follow-up will be examined for its potential to allow examination of the primary endpoint with full power.
次要结局
- Assessment of anxiety of patients monitored with STMDDM compared to patients monitored with usual care(Up to 102 weeks after randomization)
- Cumulative direct healthcare costs (in the United States) of patients monitored with STMDDM versus usual care(Up to 48 weeks after randomization)
- Assessment of quality of life of patients monitored with STMDDM versus patients monitored with usual care(Up to 102 weeks after randomization)
研究者
研究点 (1440)
Loading locations...
相似试验
已完成
3 期
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) PatientsChronic Kidney DiseaseNCT00985426Dynavax Technologies Corporation521
Unknown
不适用
Randomized Trial Comparing Two Sirolimus-Eluting Stents in Diabetes MellitusDiabetes MellitusAcute Coronary SyndromeCoronary Artery DiseaseNCT04660240Instituto Nacional de Cardiologia Ignacio Chavez860
已完成
不适用
Hemopatch Compared to TachoSil in Postoperative Air Leak Duration After Pulmonary ResectionAir Leak From LungNCT03450265Baxter Healthcare Corporation279
招募中
3 期
A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 MedicinesUncomplicated Plasmodium Falciparum MalariaNCT05951595University of Oxford1,680
已完成
不适用
A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk WomenEpithelial Ovarian CancerNCT01121640Fred Hutchinson Cancer Center854